Mode
Text Size
Log in / Sign up
N/A N=135

Post-Approval Study of the R3 Biolox Delta Ceramic Acetabular System - Europe

Degenerative Joint Disease of Hip

Enrolled (actual)
135
Serious AEs
61.5%
Results posted
May 2024
Primary outcome: Primary: Implant Survivorship — 133; 2 Participants

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Smith & Nephew Orthopaedics AG
Primary completion
Oct 2021

Outcome Measures

OutcomeResultp-value
PRIMARY
Implant Survivorship
133; 2
SECONDARY
Modified Harris Hip Score (mHHS)
47.9; 92; 92.5; 92; 92.6
SECONDARY
Number of Participants With Radiographic Success
111; 4; 101; 5; 90; 5

Summary

The purpose of this prospective, multicenter, single arm study is to confirm the long-term safety and effectiveness of the R3 delta Ceramic Acetabular System PMA (P150030) by evaluating long-term (10 years after surgery) follow-up results.

Eligibility Criteria

Inclusion Criteria

Patient is 18-75 years old and he/she is skeletally mature

  • Patient requires primary total hip arthroplasty due to non-inflammatory degenerative joint disease (e.g. osteoarthritis, post-traumatic arthritis, avascular necrosis, dysplasia/ developmental dysplasia of the hip) or inflammatory joint disease (e.g., rheumatoid arthritis)
  • Patient has met an acceptable preoperative medical clearance and is free from or treated for cardiac, pulmonary, hematological, etc., conditions that would pose excessive operative risk
  • The patient is willing to comply the follow-up schedule

Exclusion Criteria

Patient has active infection or sepsis (treated or untreated)

  • Patient is a prisoner or has an emotional or neurological condition that would pre-empt their ability or unwillingness to participate in the study including mental illness, mental retardation, linguistic insufficiencies (i.e. immigrants), or drug/alcohol abuse,
  • Patients with acute hip trauma (femoral neck fracture)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03566082). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search